Trinity Biotech plc has launched a new testing service for preeclampsia.
The service is planned to be rolled out in Q3 2025 through Trinity Biotech’s New York-based reference laboratory.
Trinity Biotech will offer the FDA-cleared PreClara Ratio (sFlt-1/PlGF) biomarker test as part of a strategic collaboration with Thermo Fisher Scientific, enhancing Trinity Biotech’s capabilities to deliver critical maternal health diagnostics.
Approximately 500,000 women in the US every year are impacted by hypertensive disorders of pregnancy – a leading cause of maternal and neonatal complications. The sFlt-1/PlGF test provides time-sensitive, clinically actionable insights that support healthcare providers in making earlier, more informed decisions for hospitalized patients. By helping to assess the likelihood of progression to severe preeclampsia, the test enables more targeted and timely management of care for this high-risk patient population.
“This launch represents an important strategic milestone in Trinity Biotech’s maternal health strategy, significantly enhancing our position in this critical clinical area, and is a further step in our transformation to focus on new technology platforms in large impact areas,” said John Gillard, CEO of Trinity Biotech.
“Our expanding maternal health portfolio reflects our continued commitment to delivering value for our shareholders through innovations that address urgent healthcare needs, and as a company we are very proud to be part of supporting patients in this important healthcare area.”
The clinical and economic value of the sFlt-1/PlGF test is reinforced by recent US-based studies. Research published in March 2025 demonstrated potential neonatal cost savings exceeding $10m per 1,000 patients when the test is incorporated into standard care. These savings primarily stem from reduced preterm deliveries and neonatal intensive care unit admissions, highlighting both clinical efficacy and economic benefit.
The launch of the testing service lays the groundwork for the anticipated commercial introduction of PrePsia, Trinity Biotech’s preeclampsia risk assessment technology designed for use in early pregnancy.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
